Product in Healthtech · 2022-05-24 · 28 min
JOIN us on September 22nd for our FREE event! Welcome back to Product in Healthtech, a community for healthtech product leaders by product leaders. Today’s guest is Jack Boren, managing director at EPIC Ventures out of Salt Lake City, Utah. EPIC invests in a range of verticals, including biotech, digital health, enterprise software, and cybersecurity. We recently sat down with Jack to kick off our series of talks with healthtech investors. Jack takes us behind the scenes at how they perform technology diligence at product-led companies. He also chats with us about remote patient monitoring, design thinking, customer experience, and more. This series is hosted by Ian Harris, President and CEO at Vynyl, a software development and design firm. Want to be a guest or request a topic discussion: info@productinhealthtech.com Get in touch with Jack: jack@epicvc.com Ian Harris: Jack Boren: Product in Healthtech is community for healthtech product leaders, by product leaders. For more information, and to
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Episode 60: “Startups Are Hype Machines” | Carta’s Peter Walker on Angel Exits, SAFEs, and AI-Age InvestingThe Diligent Observer Podcast · on Angel investing86 / 100
ramzi rizk / wip capitalslice podcast · on Angel investing82 / 100
How Smart Founders Raise Capital in 2026 (VC Reality Check)Ventures from The Valley · on Angel investing81 / 100
Disrupting Airlines, Streaming, and Healthcare for GoodThe Shift Code · on digital health79 / 100
61 | Is Your Business Right for Venture Capital with Natalia Bishop, Owner of Story LouisvilleWoman-Owned Wallet: The Podcast · on Angel investing75 / 100
Niterra VenturesImpacTV · on digital health74 / 100
Derek Baird from Switchboard Health68 / 100
Building the Future of Brain Training with EEG Headphones - with John Golden, CEO of Vital Neuro64 / 100
Transforming Health Tech Go-to-Market: How Bonfire Analytics Drives Sales Efficiency65 / 100
Radical Clarity in Drug Pricing: How Rescription Uses the 340B Program and Patented Tech to Lower Costs79 / 100
Claire Manneh of Datavant